Table: Aska Pharmaceutical -2015/16 group results
May 12 (Reuters)-
Aska Pharmaceutical Co Ltd
CONSOLIDATED FINANCIAL HIGHLIGHTS
(in billions of yen unless specified)
Year ended Year ended Year to NEXT
Mar 31, 2016 Mar 31, 2015 Mar 31, 2017 YEAR
LATEST YEAR-AGO COMPANY COMPANY
RESULTS RESULTS FORECAST H1 FORECAST
Sales 43.22 42.91 45.00 22.00
(+0.7 pct) (+8.6 pct) (+4.1 pct) (+4.2 pct)
Operating 1.17 1.43 1.00 200 mln
(-18.1 pct) (+99.1 pct) (-14.3 pct) (-60.5 pct)
Recurring 1.52 1.72 1.20 350 mln
(-11.6 pct) (+67.0 pct) (-21.2 pct) (-49.2 pct)
Net
Net 701 mln 1.19 1.00 250 mln
(-41.2 pct) (+140.9 pct) (+42.6 pct) (-36.9 pct)
EPS 25.15 yen 42.89 yen 35.81 yen 8.95 yen
Ann Div 14.00 yen 14.00 yen 14.00 yen
-Q2 Div 7.00 yen 7.00 yen 7.00 yen
-Q4 Div 7.00 yen 7.00 yen 7.00 yen
NOTE - Aska Pharmaceutical Co Ltd.
*Second Net profit row denotes profit attributable to owners ofthe parent
To see Company Overview page, click reuters://REALTIME/verb=CompanyData/ric=4514.T
((Tokyo Headline News Desk +813 6441 1812))
Recent news on ASKA Pharmaceutical Holdings
See all newsTable: Aska Pharmaceutical Holdings -Q1 group results
Brief: Dalton Investment Strongly Oppose Conditional Activation Of Countermeasures Announced By Aska Pharmaceutical Holdings On May 25
Brief: Aska Pharmaceutical -Plan To Put To Shareholders Proposal On Countermeasures Against Potential Large-Scale Share Purchase By Dalton And Related Parties
Table: Aska Pharmaceutical Holdings -2025/26 group results
Table: Aska Pharmaceutical Holdings -2025/26 group results